Press Release Winners Announced for 2022 Boulle-SEI Awards for Immunology Research 16th December 2022 For the second consecutive year, the Spanish Society of Immunology (SEI) and Jean Boulle Group have recognized the work of research, diagnosis and treatment of immune system pathologies through the second Boulle-SEI Awards. This year the Boulle-SEI Award judging panel, composed…
Press Release Jean Boulle Group Receives US$47 million Cash Investment from a New Major Strategic Investor in its Proprietary VDYNE Technology – Set to Disrupt the Market for Heart Valve Replacement Luxembourg 24 October 2022 The Jean Boulle Group (“the Group”) is pleased to announce a US$47 million cash investment (“the Investment”) in Jean Boulle Medtech’s…
Jean Boulle Medtech Ltd is pleased to announce that VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company founded by Jean Boulle Medtech to develop a transcatheter replacement tricuspid valve, has closed a $21 million, heavily subscribed Series C financing.
VDYNE, INC, Inc. (“VDYNE” or “the Company”), a privately held medical device company founded by Jean Boulle Medtech to develop a transcatheter replacement valve for the treatment of tricuspid regurgitation (“TR”), announced today that it is the co-recipient of the Innovations in Cardiovascular Interventions & High-Tech Science Industry World Startup Competition 2020. This award is one of the world’s most significant and prestigious awards for medical interventions (ICI 2020).
A surgical team at Royal Brompton Hospital successfully completed five ‘beating heart’ mitral valve repair operations last week, using a pioneering treatment not offered anywhere else in England, Scotland or Wales.
A surgical team at Royal Brompton Hospital successfully completed five ‘beating heart’ mitral valve repair operations last week, using a pioneering treatment not offered anywhere else in England, Scotland or Wales.